Research progress of virus like particles vaccine

doi:10.14088/j.cnki.issn0439-8114.2021.22.001

Abstract

Abstract: Virus like particles（VLPs） vaccine can form a protein particle structure similar to the virus by expressing the structural protein assembly of the virus, simulate the process of the virus entering the body, activate the immune response of the body, so as to achieve the purpose of resisting the virus. VLPs vaccine has become a popular choice for vaccine preparation because of its high efficiency and safety. Classification of VLPs vaccines, advantages, expression systems, purification assembly, identification methods, immune pathways, modified vaccine and other aspects were reviewed in order to provide reference for the study of VLPs vaccines.

Key words: virus like particles, vaccine, modification, expression system, immunity

CLC Number:

S961.6

TAN Kun, ZHANG Li-lin. Research progress of virus like particles vaccine[J]. HUBEI AGRICULTURAL SCIENCES, 2021, 60(22): 5-10.

References

[1] KUSHNIR N, STREATFIELD S J, YUSIBOV V.Virus-like particles as a highly efficient vaccine platform: Diversity of targets and production systems and advances in clinical development[J]. Vaccine, 2012,31(1):58-83.
[2] JENNINGS G T, BACHMANN M F.The coming of age of virus-like particle vaccines[J]. Biol Chem, 2008,389(5):521-536.
[3] LI T C, YAMAKAWA Y, SUZUKI K, et al.Expression and self-assembly of empty virus-like particles of hepatitis E virus[J]. Journal of Virology, 1997,71(10):7207-7213.
[4] DING F X, WANG F, LU Y M, et al.Multiepitope peptide-loaded virus-like particles as a vaccine against hepatitis B virus-related hepatocellular carcinoma[J]. Hepatology, 2009,49(5):1492-1502.
[5] LATHAM T, GALARZA J M.Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins[J]. Journal of Virology, 2001,75(13):6154-6165.
[6] DE FILETTE M, FIERS W, MARTENS W, et al.Improved design and intranasal delivery of an M2e-based human influenza A vaccine[J]. Vaccine, 2006,24(44-46):6597-6601.
[7] WU Z, CHEN K, YILDIZ I, et al.Development of viral nanoparticles for efficient intracellular delivery[J]. Nanoscale, 2012,4(11):3567-3576.
[8] BACHMANN M F, JENNINGS G T.Vaccine delivery: A matter of size, geometry, kinetics and molecular patterns[J]. Nat Rev Immunol, 2010,10(11):787-796.
[9] BACHMANN M F, KALINKE U, ALTHAGE A, et al.The role of antibody concentration and avidity in antiviral protection[J]. Science, 1997,276(5321):2024-2027.
[10] ADOLPH D W, BUTLER P J.Studies on the assembly of a spherical plant virus. III. Reassembly of infectious virus under mold conditions[J]. J Mol Biol, 1977,109(2):345-357.
[11] TANG T, WENG T, JIA H, et al.Harnessing the layer-by-layer assembly technique to design biomaterials vaccines for immune modulation in translational applications[J]. Biomater Sci, 2019,7(3):715-732.
[12] VALENZUELA P, MEDINA A, RUTTER W J, et al.Synthesis and assembly of hepatitis B virus surface antigen particles in yeast[J]. Nature, 1982,298(5872):347-350.
[13] CORTES-PEREZ N G, KHARRAT P, LANGELLA P, et al. Heterologous production of human papillomavirus type-16 L1 protein by a lactic acid bacterium[J]. BMC Res Notes, 2009,2:167.
[14] WU T, LI S W, ZHANG J, et al.Hepatitis E vaccine development: A 14 year odyssey[J]. Hum Vaccin Immunother, 2012,8(6):823-827.
[15] BROWN S D, FIEDLER J D, FINN M G.Assembly of hybrid bacteriophage Qβ virus-like particles[J]. Biochemistry, 2009,48(47):11155-11157.
[16] HWANG D J, ROBERTS I M, WILSON T M.Expression of tobacco mosaic virus coat protein and assembly of pseudovirus particles in Escherichia coli[J]. Proc Natl Acad Sci USA, 1994,91(19):9067-9071.
[17] ZHAO Q, ALLEN M J, WANG Y, et al.Disassembly and reassembly improves morphology and thermal stability of human papillomavirus type 16 virus-like particles[J]. Nanomedicine, 2012,8(7):1182-1189.
[18] LIU F, WU X, LI L, et al.Use of baculovirus expression system for generation of virus-like particles: Successes and challenges[J]. Protein Expr Purif, 2013,90(2):104-116.
[19] AHMAD M, HIRZ M, PICHLER H, et al.Protein expression in Pichia pastoris:Recent achievements and perspectives for heterologous protein production[J]. Appl Microbiol Biotechnol, 2014,98(12):5301-5317.
[20] LAI H, CHEN Q.Bioprocessing of plant-derived virus-like particles of norwalk virus capsid protein under current good manufacture practice regulations[J]. Plant Cell Rep, 2012,31(3):573-584.
[21] BOER E, STEINBORN G, KUNZE G, et al.Yeast expression platforms[J]. Appl Microbiol Biotechnol, 2007,77(3):513-523.
[22] BAGHBAN R, FARAJNIA S, RAJABIBAZL M, et al.Yeast expression systems:Overview and recent advances[J]. Mol Biotechnol, 2019,61(5):365-384.
[23] 李国坤, 高向东, 徐晨. 哺乳动物细胞表达系统研究进展[J]. 中国生物工程杂志, 2014,34(1):95-100.
[24] SCOTTI N, RYBICKI E P.Virus-like particles produced in plants as potential vaccines[J]. Expert Rev Vaccines, 2013,12(2):211-224.
[25] RYBICKI E P.Plant-made vaccines for humans and animals[J]. Plant Biotechnol J, 2010,8(5):620-637.
[26] VICENTE T, MOTA J P, PEIXOTO C, et al.Rational design and optimization of downstream processes of virus particles for biopharmaceutical applications:Current advances[J]. Biotechnol Adv, 2011,29(6):869-878.
[27] VICENTE T, ROLDAO A, PEIXOTO C, et al.Large-scale production and purification of VLP-based vaccines[J]. J Invertebr Pathol, 2011,107:S42-S48.
[28] SALAZAR O, ASENJO J A.Enzymatic lysis of microbial cells[J]. Biotechnol Lett, 2007,29(7):985-994.
[29] CULL M, MCHENRY C S.Preparation of extracts from prokaryotes[J]. Methods Enzymol, 1990,182:147-153.
[30] ZELTINS A.Construction and characterization of virus-like particles:A review[J]. Mol Biotechnol, 2013,53(1):92-107.
[31] ZHAO Q, MODIS Y, HIGH K, et al.Disassembly and reassembly of human papillomavirus virus-like particles produces more virion-like antibody reactivity[J]. Virol J, 2012,9:52.
[32] MORENWEISER R.Downstream processing of viral vectors and vaccines[J]. Gene Ther, 2005,121:103-110.
[33] SANCHEZ-RODRIGUEZ S P, MUNCH-ANGUIANO L, ECH-EVERRIA O, et al. Human parvovirus B19 virus-like particles:In vitro assembly and stability[J]. Biochimie, 2012,94(3):870-878.
[34] ZHAO Q, LI S, YU H, et al.Virus-like particle-based human vaccines:Quality assessment based on structural and functional properties[J]. Trends Biotechnol, 2013,31(11):654-663.
[35] DESCHUYTENEER M, ELOUAHABI A, PLAINCHAMP D, et al.Molecular and structural characterization of the L1 virus-like particles that are used as vaccine antigens in Cervarix^TM, the AS04-adjuvanted HPV-16 and -18 cervical cancer vaccine[J]. Hum Vaccin, 2010,6(5):407-419.
[36] MOHSEN M O, GOMES A C, CABRAL-MIRANDA G, et al.Delivering adjuvants and antigens in separate nanoparticles eliminates the need of physical linkage for effective vaccination[J]. J Control Release, 2017,251:92-100.
[37] MANOLOVA V, FLACE A, BAUER M, et al.Nanoparticles target distinct dendritic cell populations according to their size[J]. Eur J Immunol, 2008,38(5):1404-1413.
[38] FAKRUDDIN J M, LEMPICKI R A, GORELICK R J, et al.Noninfectious papilloma virus-like particles inhibit HIV-1 replication:Implications for immune control of HIV-1 infection by IL-27[J]. Blood, 2007,109(5):1841-1849.
[39] RAGHUNANDAN R.Virus-like particles: innate immune stimulators[J]. Expert Rev Vaccines, 2011,10(4):409-411.
[40] KELLER S A, BAUER M, MANOLOVA V, et al.Cutting edge:Limited specialization of dendritic cell subsets for MHC class II-associated presentation of viral particles[J]. J Immunol, 2010,184(1):26-29.
[41] PONTERIO E, PETRIZZO A, DI BARTOLO I, et al.Pattern of activation of human antigen presenting cells by genotype GII.4 norovirus virus-like particles[J]. J Transl Med, 2013,11:127.
[42] GRGACIC E V, ANDERSON D A.Virus-like particles:Passport to immune recognition[J]. Methods, 2006,40(1):60-65.
[43] YAN D, WEI Y Q, GUO H C, et al.The application of virus-like particles as vaccines and biological vehicles[J]. Appl Microbiol Biotechnol, 2015,99(24):10415-10432.
[44] JENNINGS G T, BACHMANN M F.The coming of age of virus-like particle vaccines[J]. Biol Chem, 2008,389(5):521-536.
[45] CARRASCO Y R, BATISTA F D.B cells acquire particulate antigen in a macrophage-rich area at the boundary between the follicle and the subcapsular sinus of the lymph node[J]. Immunity, 2007,27(1):160-171.
[46] BACHMANN M F, ROHRER U H, KUNDIG T M, et al.The influence of antigen organization on B cell responsiveness[J]. Science, 1993,262(5138):1448-1451.
[47] GOMES A C, FLACE A, SAUDAN P, et al.Adjusted particle size eliminates the need of linkage of antigen and adjuvants for appropriated t cell responses in virus-like particle-based vaccines[J]. Front Immunol, 2017,8:226.
[48] KRIEG A M.Therapeutic potential of toll-like receptor 9 activation[J]. Nat Rev Drug Discov, 2006,5(6):471-484.
[49] GOMES A C, MOHSEN M, BACHMANN M F.Harnessing nanoparticles for immunomodulation and vaccines[J]. Vaccines (Basel), 2017,5(1):6.
[50] WU Z, CHEN K, YILDIZ I, et al.Development of viral nanoparticles for efficient intracellular delivery[J]. Nanoscale, 2012,4(11):3567-3576.
[51] ROSTOVTSEV V V, GREEN L G, FOKIN V V, et al.A stepwise huisgen cycloaddition process: Copper(I)-catalyzed regioselective “ligation” of azides and terminal alkynes[J]. Angew Chem Int Ed Engl, 2002,41(14):2596-2599.
[52] YIN Z, COMELLAS-ARAGONES M, CHOWDHURY S, et al.Boosting immunity to small tumor-associated carbohydrates with bacteriophage qbeta capsids[J]. ACS Chem Biol, 2013,8(6):1253-1262.
[53] STEFANETTI G, SAUL A, MACLENNAN C A, et al.Click chemistry applied to the synthesis of salmonella typhimurium O-antigen glycoconjugate vaccine on solid phase with sugar recycling[J]. Bioconjug Chem, 2015,26(12):2507-2513.
[54] WASHINGTON-HUGHES C L, CHENG Y, DUAN X, et al. In vivo virus-based macrofluorogenic probes target azide-labeled surface glycans in MCF-7 breast cancer cells[J]. Mol Pharm, 2013,10(1):43-50.
[55] ALJABALI A A, SHUKLA S, LOMONOSSOFF G P, et al.CPMV-DOX delivers[J]. Mol Pharm, 2013,10(1):3-10.
[56] GREGSON A L, OLIVEIRA G, OTHORO C, et al.Phase I trial of an alhydrogel adjuvanted hepatitis B core virus-like particle containing epitopes of Plasmodium falciparum circumsporozoite protein[J]. PLoS One, 2008,3(2):e1556.
[57] BALTABEKOVA A, SHAGYROVA Z, KAMZINA A S, et al.Split Core technology allows efficient production of virus-like particles presenting a receptor-contacting epitope of human IgE[J]. Mol Biotechnol, 2015,57(8):746-755.
[58] WALKER A, SKAMEL C, NASSAL M.SplitCore:An exceptionally versatile viral nanoparticle for native whole protein display regardless of 3D structure[J]. Sci Rep, 2011,1:5.
[59] PEYRET H, GEHIN A, THUENEMANN E C, et al.Tandem fusion of hepatitis B core antigen allows assembly of virus-like particles in bacteria and plants with enhanced capacity to accommodate foreign proteins[J]. PLoS One, 2015,10(4):e120751.
[60] BROWN A D, NAVES L, WANG X, et al.Carboxylate-directed in vivo assembly of virus-like nanorods and tubes for the display of functional peptides and residues[J]. Biomacromolecules, 2013,14(9):3123-3129.
[61] GOLDINGER S M, DUMMER R, BAUMGAERTNER P, et al.Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8(+) T-cell responses in melanoma patients[J]. Eur J Immunol, 2012,42(11):3049-3061.
[62] MOHSEN M O, ZHA L S, CABRAL-MIRANDA G.et al.Major findings and recent advances in virus-like particle (VLP)-based vaccines[J]. Seminars in immunology,2017,34:123-132.
[63] SHOUVAL D, ROGGENDORF H, ROGGENDORF M.Enhanced immune response to hepatitis B vaccination through immunization with a Pre-S1/Pre-S2/S vaccine[J]. Medical microbiology and immunology, 2015,204(1):57-68.